Document:

<PAGE>
                                                                    Exhibit 10.1
                            FOURTH AMENDMENT TO LEASE

      THIS FOURTH AMENDMENT TO LEASE (the "Fourth Amendment") is made as of this
31st day of October, 2005, by and between MERRILL PLACE, LLC, a Washington
limited liability company ("Landlord"), and CRAY INC., formerly known as Tera
Computer Company, a Washington corporation ("Tenant").

      RECITALS:

      A. Landlord is the owner of certain real property and the improvements
situated thereon having a postal address of 411 First Avenue South, Seattle,
Washington 98104 (the "Property"). The improvements on the Property are commonly
known as the Sellar Hambach Building, the Schwabacher Building and the Warehouse
Building.

      B. Landlord and Tenant entered into a Lease Agreement, dated November 21,
1997, as amended by an Amendment to Lease dated June 15, 1999, a Second
Amendment to Lease dated December 18, 2000, and a Third Amendment to Lease dated
September 28, 2001 (the "Third Amendment") (hereinafter collectively called the
"Lease"). The Lease provides for the lease by Landlord to Tenant of certain
Premises in the Sellar Hambach Building and the Schwabacher Building, consisting
of approximately 86,152 square feet.

      C. Landlord has agreed to take back the Leased Third Floor Space (as
defined in the Third Amendment) and all of the space leased to Tenant on the
seventh floor of the Sellar Hambach Building (the "Seventh Floor Space"),
subject to the terms and conditions contained herein.

      NOW, THEREFORE, for and in consideration of the recitals, which are
incorporated herein, and other good and valuable consideration, the parties
hereto agree that the Lease shall be, and the same hereby is, amended as
follows:

      1. Surrender and Acceptance of Leased Third Floor Space. Effective as of
October 1, 2005 (the "Third Floor Surrender Date"), Landlord hereby takes back,
and Tenant hereby surrenders and waives all rights to lease and occupy, the
Leased Third Floor Space (consisting of approximately 9,082 square feet).
Landlord and Tenant further agree that as of the Third Floor Surrender Date,
Section 1(b) of the Lease shall be amended such that the total floor area of the
Premises shall be approximately 77,070 rentable square feet and Section 1(d) of
the Lease which sets forth Tenant's Percentage of the Building(s) shall be
reduced accordingly to 60.21% (77,070 divided by 127,992). In consideration for
Landlord's agreement to take back the Leased Third Floor Space, Tenant shall
issue Landlord 20,000 shares of the common stock of Tenant on or before
October 31, 2005.

      2. Rights to and Obligations of Leased Third Floor Space; Reconciliation.
With respect to the Leased Third Floor Space, each of the parties hereto
acknowledge performance of all obligations of the other party under this Lease
or otherwise in connection with the Leased Third Floor Space through and
including the date of this Amendment, and agree that, from and

                                       1

<PAGE>
after the Third Floor Surrender Date, the Lease and all rights and obligations
of the parties thereunder with regard to the Leased Third Floor Space shall be
deemed to have expired and terminated as fully and completely and with the same
force and effect as if such date were the termination date set forth in the
Lease to the Leased Third Floor Space. In addition, any and all rights and
obligations of the parties which may have arisen in connection with the Leased
Third Floor Space, other than those which would, by their express terms, survive
the termination of the Lease, shall be deemed to have expired and terminated as
of the Third Floor Surrender Date. Notwithstanding the foregoing, Landlord and
Tenant do hereby acknowledge and agree that, as to the Leased Third Floor Space,
year end adjustments (reconciliations) pertaining to the Leased Third Floor
Space, as prescribed by the Lease, may not have occurred as of the Third Floor
Surrender Date, and therefore the provisions of the Lease relating to the
requirement for year end statements, reconciliations, and payments for
deficiency or overpayment of the extra charges based on use, however they may be
described under the Lease, shall continue in force until they are otherwise
resolved under the Lease, or eighteen (18) months from the Third Floor Surrender
Date, whichever occurs first.

      3. Surrender and Acceptance of Seventh Floor Space. Effective on January
1, 2006 (the "Seventh Floor Surrender Date"), Landlord shall take back, and
Tenant shall surrender and waive all right to lease and occupy, the Seventh
Floor Space (consisting of approximately 17,457 square feet). Landlord and
Tenant further agree that as of the Seventh Floor Surrender Date, Section 1(b)
of the Lease shall be amended such that the total floor area of the Premises
shall be approximately 59,613 rentable square feet and Section 1(d) of the Lease
which sets forth Tenant's Percentage of the Building(s) shall be reduced
accordingly to 46.58% (59,613 divided by 127,992). In consideration of
Landlord's agreement to take back the Seventh Floor Space, Tenant shall issue
Landlord 50,000 shares of the common stock of Tenant on or before January 1,
2006.

      4. Rights to and Obligations of Seventh Floor Space; Reconciliation. With
respect to the Seventh Floor Space, each of the parties hereto acknowledge
performance of all obligations of the other party under this Lease or otherwise
in connection with the Seventh Floor Space through and including the date of
this Amendment, and agree that, from and after the Seventh Floor Surrender Date,
the Lease and all rights and obligations of the parties thereunder with regard
to the Seventh Floor Space shall be deemed to have expired and terminated as
fully and completely and with the same force and effect as if such date were the
termination date set forth in the Lease to the Seventh Floor Space. In addition,
any and all rights and obligations of the parties which may have arisen in
connection with the Seventh Floor Space, other than those which would, by their
express terms, survive the termination of the Lease, shall be deemed to have
expired and terminated as of the Seventh Floor Surrender Date. Notwithstanding
the foregoing, Landlord and Tenant do hereby acknowledge and agree that, as to
the Seventh Floor Space, year end adjustments (reconciliations) pertaining to
the Seventh Floor Space, as prescribed by the Lease, may not have occurred as of
the Seventh Floor Surrender Date, and therefore the provisions of the Lease
relating to the requirement for year end statements, reconciliations, and
payments for deficiency or overpayment of the extra charges based on use,
however they may be described under the Lease, shall continue in force until
they are otherwise resolved under the Lease, or eighteen (18) months from the
Seventh Floor Surrender Date, whichever occurs first.

                                       2

<PAGE>
      5. Restricted Shares. The shares of Tenant's common stock to be issued
pursuant to Paragraphs 1 and 3 above will be restricted stock, subject to the
provisions of Rule 144. At Landlord's request, Tenant agrees to take all
reasonable steps, in accordance with applicable securities laws, to facilitate
Landlord's sale of the restricted stock after the Rule 144, one-year holding
period and to remove the restrictive legend from the certificate after the
two-year holding period. The timely removal of the restrictive legend from the
certificates, as provided herein, is a material part of this Fourth Amendment;
provided, however, that any failure by Tenant to do so shall not impair or
rescind this Fourth Amendment.

      6. Counterparts. This Fourth Amendment may be executed in one or more
counterparts, and all of the counterparts shall constitute but one and the same
agreement, notwithstanding that all parties hereto are not signatories to the
same or original counterpart.

      7. All Other Terms Remain Unchanged. Capitalized terms not otherwise
defined herein shall have the same meaning given them in the Lease. Except as
amended herein, all other terms and conditions of the Lease shall remain
unchanged and in full force and effect.

      IN WITNESS WHEREOF, the parties have executed this Fourth Amendment as of
the date first above written.

"LANDLORD"                        MERRILL PLACE, LLC,
                                  a Washington limited liability company

                                  By:   NSD, LLC, a Washington limited liability
                                        company, its manager

                                        By   /s/  Kevin Daniels
                                        ----------------------------------------
                                             Kevin Daniels, Member

"TENANT"                          CRAY INC.,
                                  a Washington corporation

                                  By     /s/  Brian C. Henry
                                  ----------------------------------------------
                                   Its Executive Vice President and CFO

                                  By     /s/   Kenneth W. Johnson
                                  ----------------------------------------------
                                   Its  Senior Vice President

                                       3

<PAGE>
STATE OF WASHINGTON           )
                              ) ss.
COUNTY OF KING                )

      I certify that I know or have satisfactory evidence that KEVIN DANIELS is
the person who appeared before me, and said person acknowledged that he signed
this instrument, on oath stated that he was authorized to execute the instrument
and acknowledged it as a Member of NSD, LLC, in its capacity as the Manager of
MERRILL PLACE LLC, to be the free and voluntary act and deed of each of said
limited liability companies, for the uses and purposes mentioned in the
instrument.

      WITNESS my hand and official seal hereto affixed this 14th day of
November, 2005.

      [Notary Stamp]

                                    /s/  Darlene H. Hermes
                                    --------------------------------------------
                                    (Signature of Notary)
                                    Darlene H. Hermes
                                    --------------------------------------------
                                    (Print or stamp name of Notary)
                                    NOTARY PUBLIC in and for the State
                                    of Washington
                                    My Appointment Expires: 11-02-06

STATE OF WASHINGTON           )
                              ) ss.
COUNTY OF KING                )

      I certify that I know or have satisfactory evidence that Brian C. Henry
and Kenneth W. Johnson are the persons who appeared before me, and said persons
acknowledged that they signed this instrument, on oath stated that they were
authorized to execute the instrument and acknowledged it as the Executive Vice
President and Senior Vice President, respectfully, of CRAY INC., to be the free
and voluntary act and deed of said corporation, for the uses and purposes
mentioned in the instrument.

      WITNESS my hand and official seal hereto affixed this 11th day of
November, 2005.

      [Notary Stamp]

                                    /s/ Carol Lynn Cole
                                    --------------------------------------------
                                    (Signature of Notary)
                                    Carol Lynn Cole
                                    --------------------------------------------
                                    (Print or stamp name of Notary)
                                    NOTARY PUBLIC in and for the State
                                    of Washington
                                    My Appointment Expires: 11-20-07

                                       4<PAGE>

                                                                   EXHIBIT 10.60

                              EMPLOYMENT AGREEMENT

      This Employment Agreement (this "Agreement"), dated as of November 9,
2005, is between Cardiac Science Corporation. a Delaware corporation ("Cardiac
Science"), and Raymond W. Cohen ("Cohen");

                                   W I T N E S S E T H:

      WHEREAS, Cohen has served as Chairman of the Board and Chief Executive
Officer of Cardiac Science, Inc., a Delaware corporation ("Old CSI") and is a
party to a Second Amended and Restated Employment Agreement, dated as of August
20, 2004, with Old CSI (the "CSI Employment Agreement");

      WHEREAS, pursuant to an Agreement and Plan of Merger (the "Merger
Agreement"), dated as of February 28, 2005, by and among, Cardiac Science,
Quinton Cardiology Systems, Inc. ("Quinton"), Old CSI, and Heart Acquisition
Corporation ("CSI Merger Sub"), on September 1, 2005 Quinton was merged with and
into Cardiac Science and Cardiac Science continued as the surviving corporation,
and CSI Merger Submerged with and into Old CSI and Old CSI will continue as the
surviving corporation and a wholly-owned subsidiary of Cardiac Science (the
"Merger").

      WHEREAS, as a result of the Merger, Cohen was terminated as Chairman of
the Board and Chief Executive Officer of Old CSI.

      WHEREAS, Cardiac Science desires to retain the services of Cohen upon the
terms and conditions set forth herein; and

      WHEREAS, Cohen is willing to provide services to Cardiac Science upon the
terms and conditions set forth herein.

                                   A G R E E M E N T S:

      NOW, THEREFORE, for and in consideration of the foregoing premises and for
other good and valuable consideration, the sufficiency and receipt of which are
hereby acknowledged, Cardiac Science and Cohen hereby agree to enter into an
employment relationship in accordance with the terms and conditions set forth
below.

<PAGE>

1. EMPLOYMENT

      Effective as of September 1, 2005 (the "Effective Time") and until no
earlier than the date of the first annual meeting of stockholders of Cardiac
Science following the Effective Time (the "Termination Date"), Cardiac Science
will engage Cohen and Cohen will accept such engagement by Cardiac Science as
its Chairman of the Board ("Chairman"). Cohen will perform the duties of
Chairman and such other duties as may be assigned from time to time by the Board
of Directors of Cardiac Science or as may be required by Cardiac Science's
By-Laws, which relate to the business of Cardiac Science and are reasonably
consistent with Cohen's position.

2. ATTENTION AND EFFORT

      Cohen will devote his attention and efforts to Cardiac Science's business
and will serve its interests in good faith to the best of his ability during the
term of this Agreement.

3. COMPENSATION AND BENEFITS

      Cardiac Science agrees to pay or cause to be paid to Cohen, and Cohen
agrees to accept in exchange for the services rendered hereunder by him, the
following compensation:

      3.1 ANNUAL SALARY

      (a) During the period from the Effective Time through December 31, 2005,
Cohen's compensation shall consist of a salary of $29,125 per month (pro rated
for any partial month), before all customary payroll deductions.

      (b) From January 1, 2006, until the earlier of (i) the date Cohen's
engagement as Chairman of the Board has been terminated pursuant to Section 4.1
or 4.2 hereof and (ii) the Termination Date, Cohen's compensation shall consist
of an annual salary of one hundred fifty thousand dollars ($150,000), before all
customary payroll deductions. The annual salary shall be reviewed, and shall be
subject to change, by the Board of Directors of Cardiac Science (or the
Compensation Committee thereof) at least annually while Cohen is employed
hereunder.

      3.2 BENEFITS

      Cohen will be entitled to participate, subject to and in accordance with
applicable eligibility requirements, in such benefit programs, if any, as shall
be

                                      -2-
<PAGE>

provided to Cohen from time to time by action of Cardiac Science's Board of
Directors (or the Compensation Committee thereof).

4. TERMINATION

      The engagement of Cohen pursuant to this Agreement may be terminated as
follows:

      4.1. AUTOMATIC TERMINATION ON DEATH OR TOTAL DISABILITY

      This Agreement and Cohen's engagement hereunder shall terminate
automatically upon the death or total disability of Cohen. The term "total
disability" as used herein shall mean Cohen's inability to perform the duties
set forth in Section 1 hereof for a period or periods aggregating ninety (90)
calendar days (or such other period as may be required by law) in any
twelve-month period as a result of physical or mental illness, loss of legal
capacity or any other cause beyond Cohen's control, unless Cohen is granted a
leave of absence by the Board of Directors of Cardiac Science (or the
Compensation Committee thereof). Cohen and Cardiac Science hereby acknowledge
that Cohen's ability to perform the duties specified in paragraph 1 hereof is of
the essence of this Agreement. Termination hereunder shall be deemed to be
effective (a) at the end of the calendar month in which Cohen's death occurs or
(b) immediately upon a determination by the Board of Directors of Cardiac
Science (or the Compensation Committee thereof) of Cohen's total disability, as
defined herein. In the case of termination under this Section 4.1, Cohen shall
not be entitled to receive any payments or benefits under this Agreement other
than any unpaid annual salary which has accrued as of the date Cohen's
engagement terminates.

      4.2. TERMINATION DURING TERM

      Either Cardiac Science or Cohen may terminate this agreement at any time
for any reason, with or without notice. Except as provided in Section 4.3 below,
upon such termination, Cohen shall not be entitled to receive any payments or
benefits under this Agreement other than any unpaid annual salary which has
accrued as of the date Cohen's engagement terminates.

      Cohen acknowledges and understands that his engagement with the Company is
at-will and can be terminated by either party for no reason or for any reason at
any time not otherwise specifically prohibited by law or provided for in this
Agreement. Nothing in this Agreement is intended to alther Cohen's at will
employment status or obligate the Company to continue to engage Cohen for any
specific period of time, or in any specific role or geographic location. In the
event Cohen's engagement is

                                      -3-
<PAGE>

terminated, pursuant to this Section 4.2, Cohen agrees to resign as a director
and officer of Cardiac Science (and, if applicable, any subsidiary of Cardiac
Science).

      4.3. TERMINATION PAYMENTS

            4.3.1. TERMINATION BY CARDIAC SCIENCE

      If during the period commencing on the Effective Time and ending on the
Termination Date (the "Term") Cardiac Science terminates Cohen's employment
without cause (as defined below), then Cohen shall be entitled to receive the
following termination payments and benefits:

            (1) continuation of annual salary as provided in Section 3.1(a)
      and/or (b), as applicable, through the end of the Term;

            (2) continuation of benefits afforded Cohen pursuant to Section 3.2
      through the end of the Term; and

            (3) any unpaid annual salary which has accrued as of the date
      Cohen's engagement terminates.

      The severance payments and benefits described in this paragraph are
expressly contingent upon Cohen's signing upon termination a full release in a
form acceptable to Cardiac Science, and are further contingent upon Cohen's full
compliance with the terms of the Confidentiality Agreement (as defined in
paragraph 5 below) with Cardiac Science.

            4.3.2. TERMINATION BY CARDIAC SCIENCE FOR CAUSE

      If, during the Term (or thereafter) Cohen is terminated by Cardiac Science
for Cause, Cohen shall not be entitled to receive any payments or benefits
hereunder other than any unpaid annual salary which has accrued as of the date
Cohen's engagement terminates.

            4.3.3. TERMINATION BY COHEN

      If, during the Term (or thereafter) Cohen voluntarily terminates his
employment, Cohen shall not be entitled to receive any payments or benefits
hereunder other than any unpaid annual salary which has accrued as of the date
Cohen's engagement terminates.

                                      -4-
<PAGE>

            4.3.4. CAUSE

      Wherever reference is made in this Agreement to termination being with or
without Cause, "Cause" shall be limited to the occurrence of one or more of the
following events:

            (a) willful misconduct, insubordination, or dishonesty in the
      performance of Cohen's duties or other knowing and material violation of
      Cardiac Science's policies and procedures in effect from time to time
      which results in a material adverse effect on Cardiac Science or the
      Successor Cardiac Science;

            (b) the continued failure of Cohen to satisfactorily perform his
      duties after receipt of written notice that identifies the areas in which
      Cohen's performance is deficient;

            (c) willful actions (or intentional failures to act) in bad faith by
      Cohen with respect to Cardiac Science that materially impair Cardiac
      Science's business, goodwill or reputation;

            (d) conviction of Cohen of a felony involving an act of dishonesty,
      moral turpitude, deceit or fraud, or the commission of acts that could
      reasonably be expected to result in such a conviction; or

            (e) any material violation by Cohen of Cohen's Confidentiality
      Agreement.

5. CONFIDENTIALITY AGREEMENT

      Cohen is subject to, and this Employment Agreement is conditioned on
agreement to, the terms of the Non-Disclosure Agreement (the "Confidentiality
Agreement") entered into by Cohen (with either Old CSI, Cardiac Science, or
both) and the terms of the Confidentiality Agreement shall survive the
termination of Cohen's engagement hereunder.

6. ASSIGNMENT

      This Agreement is personal to Cohen and shall not be assignable by Cohen.
Cardiac Science may assign its rights hereunder to (a) any other corporation
resulting from any merger, consolidation or other reorganization to which
Cardiac Science is a party or (b) any other corporation, partnership,
association or other person to which Cardiac Science may transfer all or
substantially all of the assets and business of

                                      -5-
<PAGE>

Cardiac Science existing at such time. All of the terms and provisions of this
Agreement shall be binding upon and shall inure to the benefit of and be
enforceable by the parties hereto and their respective successors and permitted
assigns.

7. ARBITRATION

      Any controversies or claims arising out of or relating to this Agreement
shall be fully and finally settled by arbitration in accordance with the
Employment Arbitration Rules of the American Arbitration Association then in
effect (the "AAA Rules"), conducted by one arbitrator either mutually agreed
upon by Cardiac Science and Cohen or chosen in accordance with the AAA Rules,
except that the parties thereto shall have any right to discovery as would be
permitted by the Federal Rules of Civil Procedure for a period of 90 days
following the commencement of such arbitration and the arbitrator thereof shall
resolve any dispute which arises in connection with such discovery. The
prevailing party shall be entitled to costs, expenses and reasonable attorneys'
fees, and judgment upon the award rendered by the arbitrator may be entered in
any court having jurisdiction thereof. It is further agreed by the parties that
the venue for any arbitration proceedings shall be within the state of
Washington.

8. AMENDMENTS IN WRITING

      No amendment, modification, waiver, termination or discharge of any
provision of this Agreement, nor consent to any departure therefrom by either
party hereto, shall in any event be effective unless the same shall be in
writing, specifically identifying this Agreement and the provision intended to
be amended, modified, waived, terminated or discharged and signed by Cardiac
Science and Cohen, and each such amendment, modification, waiver, termination or
discharge shall be effective only in the specific instance and for the specific
purpose for which given. No provision of this Agreement shall be varied,
contradicted or explained by any oral agreement, course of dealing or
performance or any other matter not set forth in an agreement in writing and
signed by Cardiac Science and Cohen.

9. APPLICABLE LAW

      This Agreement shall in all respects, including all matters of
construction, validity and performance, be governed by, and construed and
enforced in accordance with, the laws of the State of Washington, without regard
to any rules governing conflicts of laws.

                                      -6-
<PAGE>

10. ENTIRE AGREEMENT

      This Agreement, on and as of the date hereof, constitutes the entire
agreement between Cardiac Science and Cohen with respect to the subject matter
hereof and all prior or contemporaneous oral or written communications,
understandings or agreements between Cardiac Science, Old CSI and Cohen with
respect to such subject matter, including the CSI Employment Agreement, are
hereby superseded (except that Cohen remains eligible for all severance benefits
specified in the CSI Employment Agreement in connection with his termination as
Chairman and Chief Executive Officer of Old CSI as a result of the Merger).

                                      -7-
<PAGE>

      IN WITNESS WHEREOF, the parties have executed and entered into this
Agreement on the date set forth above.

                                         /s/ Raymond W. Cohen
                                         --------------------------------
                                         Raymond W. Cohen

                                         CARDIAC SCIENCE CORPORATION

                                         /s/ Michael K. Matysik
                                         --------------------------------
                                         By: Michael K. Matysik
                                         --------------------------------
                                         Its: Senior Vice President and
                                              Chief Financial Officer

                                      -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]